Seroprevalence, Genotyping, and Monitoring of Hepatitis C Viral Loads in Patients on Antivirals in Burkina Faso.

IF 4.3 3区材料科学 Q1 ENGINEERING, ELECTRICAL & ELECTRONIC

ACS Applied Electronic Materials Pub Date : 2022-01-01 Epub Date: 2021-09-28 DOI:10.1159/000519848

Edwige T Yelemkoure, Albert T Yonli, Hermann K Sombie, Issoufou Tao, Abdou Azaque Zouré, Abdoul Karim Ouattara, Abel P Sorgho, Arsène W Zongo, Moctar T A Zeba, Isabelle T Kiendrebeogo, Prosper Bado, Madeleine K Kabré, Théodora M Zohoncon, Florencia W Djigma, Dorcas Obiri-Yeboah, Jacques Simpore

{"title":"Seroprevalence, Genotyping, and Monitoring of Hepatitis C Viral Loads in Patients on Antivirals in Burkina Faso.","authors":"Edwige T Yelemkoure, Albert T Yonli, Hermann K Sombie, Issoufou Tao, Abdou Azaque Zouré, Abdoul Karim Ouattara, Abel P Sorgho, Arsène W Zongo, Moctar T A Zeba, Isabelle T Kiendrebeogo, Prosper Bado, Madeleine K Kabré, Théodora M Zohoncon, Florencia W Djigma, Dorcas Obiri-Yeboah, Jacques Simpore","doi":"10.1159/000519848","DOIUrl":null,"url":null,"abstract":"Introduction: Hepatitis C virus (HCV) infection remains a major public health problem worldwide. In Burkina Faso, nearly 720,000 people are living with HCV, and each year about 900 people die from complications of cirrhosis or hepatocellular carcinoma. This study was planned to determine the HCV seroprevalence, characterize circulating genotypes, and monitor HCV viral loads in patients under treatment with antivirals.Methods: A total of 4,124 individuals and 167 patients in the pre-therapy program were recruited. The \"SD Bioline HCV\" kit was used for rapid screening of anti-HCV antibodies. Viral load and genotyping were performed in 167 HCV patients on antivirals using the \"Iontek HCV Quant\" and \"Iontek genotyping\" kits.Results: Prevalence of HCV was 1.65% (68/4,124), and the median viral load of participants was 5.37 log10/mL (1.32-7.67 log10/mL). Genotype 2 was predominant with a frequency of 86.23% (144/167) and appeared to be more active with higher viral load compared to 13.77% (23/167) for genotype 1 (p < 0.001). After 24 weeks of pan-genotypic direct-acting antivirals, such as sofosbuvir/daclatasvir and sofosbuvir/velpatasvir, the viral loads of all patients became undetectable.Conclusion: The responses to antivirals by the circulating genotypes indicate that the results are very satisfactory. Therefore, the prevalence of HCV in the population can be reduced through identification of cases and treatment.","PeriodicalId":3,"journal":{"name":"ACS Applied Electronic Materials","volume":null,"pages":null},"PeriodicalIF":4.3000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9501785/pdf/","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Applied Electronic Materials","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000519848","RegionNum":3,"RegionCategory":"材料科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/9/28 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"ENGINEERING, ELECTRICAL & ELECTRONIC","Score":null,"Total":0}

引用次数: 1

Abstract

Introduction: Hepatitis C virus (HCV) infection remains a major public health problem worldwide. In Burkina Faso, nearly 720,000 people are living with HCV, and each year about 900 people die from complications of cirrhosis or hepatocellular carcinoma. This study was planned to determine the HCV seroprevalence, characterize circulating genotypes, and monitor HCV viral loads in patients under treatment with antivirals.

Methods: A total of 4,124 individuals and 167 patients in the pre-therapy program were recruited. The "SD Bioline HCV" kit was used for rapid screening of anti-HCV antibodies. Viral load and genotyping were performed in 167 HCV patients on antivirals using the "Iontek HCV Quant" and "Iontek genotyping" kits.

Results: Prevalence of HCV was 1.65% (68/4,124), and the median viral load of participants was 5.37 log10/mL (1.32-7.67 log10/mL). Genotype 2 was predominant with a frequency of 86.23% (144/167) and appeared to be more active with higher viral load compared to 13.77% (23/167) for genotype 1 (p < 0.001). After 24 weeks of pan-genotypic direct-acting antivirals, such as sofosbuvir/daclatasvir and sofosbuvir/velpatasvir, the viral loads of all patients became undetectable.

Conclusion: The responses to antivirals by the circulating genotypes indicate that the results are very satisfactory. Therefore, the prevalence of HCV in the population can be reduced through identification of cases and treatment.

Abstract Image

查看原文本刊更多论文

布基纳法索使用抗病毒药物的丙型肝炎患者的血清阳性率、基因分型和病毒载量监测

丙型肝炎病毒(HCV)感染仍然是世界范围内的一个主要公共卫生问题。在布基纳法索，近72万人携带丙型肝炎病毒，每年约有900人死于肝硬化或肝细胞癌并发症。该研究旨在确定丙型肝炎病毒的血清患病率，确定循环基因型，并监测丙型肝炎病毒载量。方法:在治疗前项目中共招募了4124名个体和167名患者。采用“SD Bioline HCV”试剂盒快速筛选抗HCV抗体。使用“Iontek HCV Quant”和“Iontek基因分型”试剂盒对167例使用抗病毒药物的HCV患者进行病毒载量和基因分型。结果:HCV患病率为1.65%(68/ 4124)，参与者的中位病毒载量为5.37 log10/mL (1.32-7.67 log10/mL)。基因2型的阳性率为86.23%(144/167)，与基因1型的阳性率为13.77%(23/167)相比，基因2型的阳性率更高(p < 0.001)。在使用sofosbuvir/daclatasvir和sofosbuvir/velpatasvir等泛基因型直接作用抗病毒药物24周后，所有患者的病毒载量都无法检测到。结论:循环基因型对抗病毒药物的反应是令人满意的。因此，HCV在人群中的流行可以通过病例识别和治疗来降低。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

ACS Applied Electronic Materials Multiple-

CiteScore

7.20

自引率

4.30%

发文量

567